#Curium's #radioligandtherapy #Bexlutry has been approved in the US as a #generic – or 'radioligand equivalent' (#RLE) – of Novartis' #gastroenteropancreaticneuroendocrinetumour (GEP-NET) therapy Lutathera.

pharmaphorum.com/news/fda-bac...